Sectors
DNTH
Dianthus Therapeutics, Inc.
114.86
1 x 113.00
1 x 117.13
bid
ask
-
1.10
0.95%
1 @ 04:00 PM
114.86 +0.00 (0.00%)
| Ytd | 178.72% | |
| 1y | 453.81% |
113.29
day range
116.43
20.31
52 week range
116.47
| Open | 115.62 | Prev Close | 115.96 | Low | 113.29 | High | 116.43 | Mkt Cap | 6.42B |
| Vol | 567.65K | Avg Vol | 1.06M | EPS | -4.15 | P/E | -27.68 | Forward P/E | -24.22 |
| Beta | 0.08 | Short Ratio | 8.49 | Inst. Own | 129.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 97.22 | 200-d Avg | 70.44 | 1yr Est | 137.62 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -1.02 | N/A | N/A | N/A |
| 2026-08-04 | 2026-06 | -0.85 | -0.9 | -0.05 | -6.35% |
| 2026-05-05 | 2026-03 | -1.17 | -0.85 | 0.32 | 27.35% |
| 2026-03-09 | 2025-12 | -0.98 | -1.43 | -0.45 | -45.92% |
| 2025-11-05 | 2025-09 | -0.86 | -0.97 | -0.11 | -12.79% |
| 2025-08-07 | 2025-06 | -0.86 | -0.88 | -0.02 | -2.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-06 | Truist Securities | Upgrade | Buy | Buy |
| 2026-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-05 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-03 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-06 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform |
Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-11 | CARR EDWARD | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2026-08-06 | GARCIA MARINO | Chief Executive Officer | 65.29K | Conversion of Exercise of derivative security |
| 2026-08-09 | MCGEORGE ANNE | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-05-31 | RANDHAWA SIMRAT | Officer | 4.00K | Conversion of Exercise of derivative security |
| 2026-08-09 | READ SIMON J. | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-07-08 | SAVITZ RYAN | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 8.20M | 941.84M | 15.00% |
| 2026-06-29 | Blackrock Inc. | 4.12M | 473.66M | 7.54% |
| 2026-06-29 | T. Rowe Price Investment Management, Inc. | 3.89M | 446.63M | 7.11% |
| 2026-06-29 | Wellington Management Group, LLP | 3.23M | 370.98M | 5.91% |
| 2026-06-29 | Fairmount Funds Management LLC | 2.54M | 291.42M | 4.64% |
| 2026-06-29 | Price (T.Rowe) Associates Inc | 2.51M | 288.87M | 4.60% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.59M | 182.87M | 2.91% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.57M | 179.81M | 2.86% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.30M | 149.10M | 2.37% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.24M | 142.95M | 2.28% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.22M | 140.34M | 2.24% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 730.06K | 83.85M | 1.34% |